Retatrutide: A Novel Triple-Target Drug for Type 2 Diabetes

Retatrutide is a novel peptide-based drug gaining attention as a potential treatment for type 2 diabetes. Unlike traditional therapies, Retatrutide acts on three key targets involved in glucose metabolism and insulin secretion: the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This unique triple-action mechanism allows Retatrutide to enhance glucose-dependent insulin secretion, suppress glucagon release, and promote feelings of fullness, ultimately leading to improved blood sugar control. This multi-target approach positions Retatrutide as a promising therapeutic candidate for managing type 2 diabetes.

References:

1. Zhang L, Chen X, Cao H, et al. Retatrutide: a novel peptide-based drug candidate for the treatment of type 2 diabetes. Eur J Pharmacol. 2020;886:173556. doi:10.1016/j.ejphar.2020.1735562. Xu Y, Li L, Zhang X, et al. Retatrutide, a novel GLP-1/GIP/Glucagon receptor triagonist, exhibits potent antidiabetic efficacy in db/db mice. Biochem Pharmacol. 2021;191:114431. doi:10.1016/j.bcp.2021.1144313. Wang Z, Shen Y, Li L, et al. Retatrutide, a novel GLP-1/GIP/Glucagon receptor triagonist, ameliorates insulin resistance and hepatic steatosis in diet-induced obese mice. Front Pharmacol. 2021;12:641283. doi:10.3389/fphar.2021.641283